JP2002540168A5 - - Google Patents

Download PDF

Info

Publication number
JP2002540168A5
JP2002540168A5 JP2000607657A JP2000607657A JP2002540168A5 JP 2002540168 A5 JP2002540168 A5 JP 2002540168A5 JP 2000607657 A JP2000607657 A JP 2000607657A JP 2000607657 A JP2000607657 A JP 2000607657A JP 2002540168 A5 JP2002540168 A5 JP 2002540168A5
Authority
JP
Japan
Prior art keywords
dengue
virus
den
pdk
passaged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000607657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002540168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/008199 external-priority patent/WO2000057907A2/en
Publication of JP2002540168A publication Critical patent/JP2002540168A/ja
Publication of JP2002540168A5 publication Critical patent/JP2002540168A5/ja
Pending legal-status Critical Current

Links

JP2000607657A 1999-03-26 2000-03-24 多価デングウイルスワクチン Pending JP2002540168A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12631399P 1999-03-26 1999-03-26
US18172400P 2000-02-11 2000-02-11
US60/181,724 2000-02-11
US60/126,313 2000-02-11
PCT/US2000/008199 WO2000057907A2 (en) 1999-03-26 2000-03-24 Multivalent dengue virus vaccine

Publications (2)

Publication Number Publication Date
JP2002540168A JP2002540168A (ja) 2002-11-26
JP2002540168A5 true JP2002540168A5 (https=) 2007-05-31

Family

ID=26824502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000607657A Pending JP2002540168A (ja) 1999-03-26 2000-03-24 多価デングウイルスワクチン

Country Status (12)

Country Link
US (2) US6638514B1 (https=)
EP (1) EP1165127B1 (https=)
JP (1) JP2002540168A (https=)
KR (1) KR100721745B1 (https=)
CN (1) CN1191092C (https=)
AT (1) ATE419006T1 (https=)
AU (1) AU779280B2 (https=)
CA (1) CA2368674A1 (https=)
DE (1) DE60041250D1 (https=)
ES (1) ES2322327T3 (https=)
MX (1) MXPA01009683A (https=)
WO (1) WO2000057907A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CN101238144B (zh) * 2005-06-17 2012-09-05 赛诺菲巴斯德有限公司 登革血清型1减毒株
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
KR20110127637A (ko) * 2008-12-22 2011-11-25 칠드런스리서치인스티튜트 패혈증 검출 방법
PE20110992A1 (es) 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
DK2384761T3 (da) * 2010-05-07 2013-12-09 Deutsches Krebsforsch Modificeret gnaverparvovirus, som er i stand til formering og spredning i humane gliomer
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
ES2981476T3 (es) 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
US9730989B2 (en) 2015-07-02 2017-08-15 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
CA2999881A1 (en) 2015-09-26 2017-03-30 PrimeVax Immuno-Oncology, Inc. Compositions and methods for producing dendritic cells
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2018165373A1 (en) * 2017-03-08 2018-09-13 University Of Georgia Research Foundation, Inc. Methods and compositions related to increased viral production
SG11201912163WA (en) * 2017-06-15 2020-01-30 Primevax Immuno Oncology Inc Compositions and methods for cancer therapy with dengue virus and dendritic cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06181792A (ja) * 1992-06-05 1994-07-05 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法、およびそれに用いる組み換えウイルス
DE69426077T3 (de) 1993-05-25 2004-09-02 Wyeth Holdings Corp. Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
WO1996040933A1 (en) * 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
NZ507848A (en) * 1996-10-28 2005-01-28 Univ Washington Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell
EP1165127B1 (en) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalent dengue virus vaccine

Similar Documents

Publication Publication Date Title
JP2002540168A5 (https=)
AU2012269907B2 (en) Vaccine composition comprising an inactivated chikungunya virus strain
JP2019511533A5 (https=)
JP2010505801A5 (https=)
JP2026031938A5 (https=)
JP5091385B2 (ja) 弱毒生ワクチン
CA2116980A1 (en) Chimeric and/or growth-restricted flaviviruses
EP2345665A3 (en) Flavivirus NS1 subunit vaccine
WO2000057907A3 (en) Multivalent dengue virus vaccine
EP2278012A3 (en) Avirulent, immunogenic flavivirus chimeras
EP3010536A1 (en) Dengue virus vaccine compositions and methods of use thereof
US7790173B2 (en) Pharmaceutical compound capable of induce immune protective response against Dengue virus having the capsid protein of the Dengue virus
CA2341354C (en) Dengue viruses that are replication defective in mosquitos for use as vaccines
Chia et al. Fragment of Japanese encephalitis virus envelope protein produced in Escherichia coli protects mice from virus challenge
US11123420B2 (en) Stable live attenuated recombinant dengue vaccine
EP4604994A1 (en) Dengue vaccine formulation
Chiba et al. A case of poliomyelitis associated with infection of wild poliovirus in Qinghai Province, China, in October 1999
Simasathein et al. Dengue vaccine
WO2002074963A1 (en) Dengue viruses that are replication defective in mosquitos for use as vaccines
Putnak et al. Inactivated dengue virus vaccine
Rombaut History and future of polivaccination, a personal account
Kelly et al. Recombinant vaccine against dengue virus
BR0010969A (pt) Vacina polivalente antivìrus da dengue
HK1120431A (en) Recombinant flavivirus vaccines